A nurse is collecting data from a client who has pneumonia and a prescription for cefazolin. Which of the following findings should the nurse report to the provider prior to administering the initial dose? (Click on the exhibit tabs for additional information about the client. There are three tabs that contain separate categories of data.)

Before administering any antibiotic, the nurse must assess for contraindications that could place the client at immediate risk for harm. Cefazolin is a cephalosporin antibiotic commonly prescribed for bacterial infections such as pneumonia. Because cephalosporins have structural similarities to penicillins, clients with a penicillin allergy may be at risk for cross-sensitivity reactions. Identifying allergy history before the first dose is a critical safety priority to prevent severe hypersensitivity reactions. Rationale: A. Allergies must be reported because the client has a documented allergy to penicillin, and cefazolin is a cephalosporin that may cause cross-reactivity in some patients. Administering the medication without provider clarification could place the client at risk for allergic reactions ranging from rash to anaphylaxis. Verification of the type and severity of the allergy is essential before giving the first dose. B. A temperature of 39.3°C (102.8°F) is an expected finding in a client with pneumonia and reflects the body’s inflammatory response to infection. Fever commonly occurs alongside chills, sweating, and increased metabolic demand. Although it requires monitoring and treatment, it does not contraindicate cefazolin administration and does not need immediate provider notification. C. A chest x-ray showing left lower lobe density is consistent with pneumonia and supports the diagnosis requiring antibiotic treatment. This finding helps confirm the presence of a lower respiratory infection rather than indicating a problem with the prescribed medication. It is expected clinical evidence and does not require reporting prior to administration of cefazolin. D. A WBC count of 16,000/mm³ indicates leukocytosis, which is a common finding in bacterial infections such as pneumonia. This elevated count reflects the immune system’s response to infection and supports the need for antibiotic therapy. It is not a contraindication to cefazolin and does not require reporting before administering the initial dose.